Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2023 Filed Oct 3, 2023 20:28 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 6,617 | $1.70 | $11,248.90 |
DisclosureSEC source: 0001662579-23-000109 · wk-form4_1696364878.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,237 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 2, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:26 UTC |
GROGAN DONNA ROYDirector
|
GrantCommon Stock | 8,089 | $1.70 | $13,751.30 |
DisclosureSEC source: 0001662579-23-000107 · wk-form4_1696364777.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,827 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 2, 2023. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:23 UTC |
Boyle Scott NChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000099 · wk-form4_1695165770.xml · derivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:21 UTC |
Adams KendraChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 111,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000097 · wk-form4_1695165671.xml · derivative · entry 2 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires 2033-09-17 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:21 UTC |
Adams KendraChief Financial Officer
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000097 · wk-form4_1695165671.xml · nonDerivative · entry 1 Adams Kendra · CIK 0001991929 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,640 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on September 18, 2024, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:24 UTC |
Hirsch AndrewDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 489,600 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000102 · wk-form4_1695165874.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,600 Underlying: Common Stock · 489,600 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:23 UTC |
Schick KellyChief People Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000101 · wk-form4_1695165826.xml · derivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:23 UTC |
Fisher StewartChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000100 · wk-form4_1695165800.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 23:22 UTC |
Siegel JolieChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001662579-23-000098 · wk-form4_1695165751.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC |
Boyle Scott NChief Business Officer
|
Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,765 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 16:09 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000081 · wk-form4_1693512585.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:11 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000084 · wk-form4_1693512682.xml · derivative · entry 3 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:11 UTC |
White LaurenChief Financial Officer
|
Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000084 · wk-form4_1693512682.xml · nonDerivative · entry 2 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,686 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:11 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000084 · wk-form4_1693512682.xml · nonDerivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 7,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC |
Hirsch AndrewDirector · President & CEO
|
Tax withholdingCommon Stock | 2,205 | $2.93 | $6,460.65 |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,901 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:13 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000086 · wk-form4_1693512793.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Schick KellyChief People Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000083 · wk-form4_1693512648.xml · derivative · entry 3 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Schick KellyChief People Officer
|
Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000083 · wk-form4_1693512648.xml · nonDerivative · entry 2 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,686 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Schick KellyChief People Officer
|
Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000083 · wk-form4_1693512648.xml · nonDerivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC |
Siegel JolieChief Legal Officer
|
Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,686 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:12 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000085 · wk-form4_1693512739.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 2,250 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Fisher StewartChief Scientific Officer
|
Tax withholdingCommon Stock | 661 | $2.93 | $1,936.73 |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,076 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 20:10 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000082 · wk-form4_1693512618.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:06 UTC |
REYNO LEONARDChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 276,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662579-23-000074 · wk-form4_1689192375.xml · derivative · entry 2 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,000 Underlying: Common Stock · 276,000 shares Expires 2033-07-09 F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on July 10, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:06 UTC |
REYNO LEONARDChief Medical Officer
|
GrantCommon Stock | 61,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000074 · wk-form4_1689192375.xml · nonDerivative · entry 1 REYNO LEONARD · CIK 0001528716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,300 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on July 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 16:24 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 3,887 | $2.83 | $11,000.21 |
DisclosureSEC source: 0001662579-23-000067 · wk-form4_1688588669.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,560 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:25 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 3,976 | $2.83 | $11,252.08 |
DisclosureSEC source: 0001662579-23-000068 · wk-form4_1688588720.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,620 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:23 UTC |
GROGAN DONNA ROYDirector
|
GrantCommon Stock | 4,858 | $2.83 | $13,748.14 |
DisclosureSEC source: 0001662579-23-000066 · wk-form4_1688588615.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,738 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:22 UTC |
Salter MalcolmDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000055 · wk-form4_1686946925.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:24 UTC |
DOWNEY BRUCEDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000060 · wk-form4_1686947050.xml · derivative · entry 1 DOWNEY BRUCE · CIK 0001237257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:23 UTC |
Dubin GlennDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000059 · wk-form4_1686947027.xml · derivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:25 UTC |
Anderson Kenneth CarlDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000062 · wk-form4_1686947141.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:24 UTC |
Bessen LauraDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000061 · wk-form4_1686947089.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:23 UTC |
GROGAN DONNA ROYDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000058 · wk-form4_1686946972.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:22 UTC |
Koppikar UtpalDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000057 · wk-form4_1686946946.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 16:20 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 3,438 | $3.20 | $11,001.60 |
DisclosureSEC source: 0001662579-23-000046 · wf-form4_168063957956687.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,673 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:19 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 3,516 | $3.20 | $11,251.20 |
DisclosureSEC source: 0001662579-23-000045 · wf-form4_168063954562598.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,644 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:19 UTC |
GROGAN DONNA ROYDirector
|
GrantCommon Stock | 4,298 | $3.20 | $13,753.60 |
DisclosureSEC source: 0001662579-23-000044 · wf-form4_168063950739832.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 21:44 UTC |
Hirsch AndrewDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 367,200 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001662579-23-000034 · wf-form4_167649743141884.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,200 Underlying: Common Stock · 367,200 shares Expires 2033-02-14 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 21:44 UTC |
Hirsch AndrewDirector · President & CEO
|
GrantCommon Stock | 81,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000034 · wf-form4_167649743141884.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,606 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 15, 2024. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:45 UTC |
Boyle Scott NChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000037 · wf-form4_167649750908844.xml · derivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:45 UTC |
Boyle Scott NChief Business Officer
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000037 · wf-form4_167649750908844.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,176 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:44 UTC |
White LaurenChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000035 · wf-form4_167649747523081.xml · derivative · entry 2 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:44 UTC |
White LaurenChief Financial Officer
|
GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000035 · wf-form4_167649747523081.xml · nonDerivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,097 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:46 UTC |
Fisher StewartChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000039 · wf-form4_167649755275761.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:46 UTC |
Fisher StewartChief Scientific Officer
|
GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000039 · wf-form4_167649755275761.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,487 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.